Imunon, Inc.

IMNN Nasdaq SEC CIK 749647
Follow Imunon Weekly email: filings, results

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0$10MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26--
FY25--
FY24-−$18.6M
FY23-−$19.5M
FY22$500K−$35.9M
FY21$500K−$20.8M
FY20$500K−$21.5M
FY19$500K−$16.9M
FY18$500K−$11.9M
FY17$500K−$20.4M
FY16-−$22.1M
FY15-−$22.5M
FY14-−$25.5M
FY13-−$8.3M
FY12-−$26.6M
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearOperating marginNet margin
FY26--
FY25--
FY24--
FY23--
FY22−4984.3%−7179.6%
FY21−4201.4%−4153.8%
FY20−3697.3%−4296.7%
FY19−4113.1%−3370.3%
FY18−4213%−2376.7%
FY17−3693.7%−4080.4%
FY16--
FY15--
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26-
FY25−$14.2M
FY24−$18.9M
FY23−$19.5M
FY22−$23.4M
FY21−$16.5M
FY20−$15.6M
FY19−$20.6M
FY18−$7.2M
FY17−$16.7M
FY16−$18.4M
FY15−$20.9M
FY14−$22M
FY13−$9.6M
FY12−$22.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Imunon
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearImunonHealthcare median
FY26-−11.1%
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−7179.6%−80.4%
FY21−4153.8%−71.8%
FY20−4296.7%−62.2%
FY19−3370.3%−46.2%
FY18−2376.7%−49.6%
FY17−4080.4%−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%